Moberg Pharma
Moberg Pharma: Positive surprises (Redeye)
2019-10-01 08:04
Management once again demonstrates its commitment to building shareholder value by signing yet another significant licensing agreement for MOB-015. The deal with Taisho providing cash, making it possible to raise the shareholder payment to SEK 46.50 from the previously announced interval of SEK 43-45, but also to repay outstanding debt.
info@redeye.se (Redeye.se)
Redeye AB - Redeye.se